预约演示
更新于：2025-07-28
Clopidogrel Bisulfate
硫酸氢氯吡格雷
更新于：2025-07-28
概要
基本信息
简介Clopidogrel Bisulfate 是一种商标为 Plavix® 的药物，在1997年于美国批准上市，由施贵宝研发。其作用机制是抑制P2Y12受体，从而减少血小板活化和聚集。这随后降低了血栓的风险及其潜在的致命后果。氯吡格雷适用于治疗心肌梗塞、中风、外周血管疾病、冠状动脉疾病和脑血管疾病。由于其作为抗血小板药物的作用，氯吡格雷被证明在预防血栓引起的严重并发症（如心脏病发作、中风甚至死亡）方面具有无可估量的价值。该药物在心血管事件的管理和预防方面显示出疗效，使其成为现代医学的基本药物。 |
药物类型 小分子化药 |
别名 clopidogrel、Clopidogrel Bisufate、Clopidogrel bisulfate (USP) + [33] |
作用方式 拮抗剂 |
作用机制 P2Y12 receptor拮抗剂(嘌呤P2Y12受体拮抗剂) |
在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C16H18ClNO6S2 |
InChIKeyFDEODCTUSIWGLK-RSAXXLAASA-N |
CAS号120202-66-6 |
关联
560
项与 硫酸氢氯吡格雷 相关的临床试验NCT07012629
A EUROpean Pragmatic Multicenter Randomized Trial on Platelet Inhibition and/or Lipid Lowering Treatment in Covert Brain Infarction (CBI)
NCT07076082
Vascular Trial Associated Registry Pilot: Antiplatelet Therapies for Patients Undergoing Lower Extremity Endovascular Revascularization
NCT07025148
Switching From Clopidogrel to Low-dose Prasugrel in Patients at Dual-risk Following Percutaneous Coronary Intervention (TAILOR-BLEED-2)
100 项与 硫酸氢氯吡格雷 相关的临床结果
登录后查看更多信息
100 项与 硫酸氢氯吡格雷 相关的转化医学
登录后查看更多信息
100 项与 硫酸氢氯吡格雷 相关的专利（医药）
登录后查看更多信息
11,319
项与 硫酸氢氯吡格雷 相关的文献（医药）2025-11-01ANNALS OF VASCULAR SURGERY
Retrograde Femoral Access Flipped Antegrade Technique and its Effect on Patient Outcomes Following Lower Extremity Angiography
Article
作者: Kronick, Matthew D ; Hadro, Neal ; Strecker, Zachary ; Lin, Alex M ; Marecki, Hazel ; Norris, Marc
BACKGROUND:
Common femoral artery access is a critical step in the endovascular treatment of peripheral artery disease. Traditionally, access is obtained either by a retrograde approach from the contralateral leg with an "up-and-over" aortic bifurcation technique, or in an antegrade fashion in the ipsilateral leg. Retrograde arterial access flipped antegrade in the ipsilateral femoral artery incorporates the technical ease of retrograde access (RA) with mechanical advantages of antegrade access (AA). There are limited studies directly comparing these techniques. The objective of this study is to describe and compare the different techniques for accessing the common femoral artery for diagnostic and therapeutic endovascular infrainguinal interventions.
METHODS:
This is a retrospective cohort study of patients undergoing lower extremity diagnostic and therapeutic angiography through either contralateral retrograde (RA), ipsilateral antegrade (AA), or retrograde femoral access flipped antegrade (RAFA) between October 1st, 2018, and September 30th, 2020. Outcomes measured were technical success, complications including hematoma, hemorrhage requiring transfusion, pseudoaneurysm, and repeat operative intervention. Differences in patient and treatment characteristics were analyzed using 2-sample t-test, Fisher's exact test and Chi-squared test. Multivariable logistic regression analysis was performed to identify associations with different access techniques and study outcomes.
RESULTS:
Of the 342 lower extremity endovascular procedures, 156 (45.6%) used RA access, 82 (24.0%) AA access, and 104 (30.4%) RAFA access. There were no significant differences in the mean age, gender, and body mass index between patients undergoing different access method cohorts (P > 0.05). The RAFA cohort had a significantly higher percentage of patients taking Plavix (46%) than retrograde (24%) and antegrade (34%) patients (P < 0.001). Patients undergoing RAFA access were less commonly active smokers (P = 0.003) or had chronic obstructive pulmonary disease (P = 0.001). Fluoroscopic confirmation of arterial puncture occurred less frequently in the AA cohort (P = 0.037). Technical success rate during therapeutic intervention was highest in the AA cohort (RA, 84%; AA, 98%; RAFA, 91%; P = 0.024). The AA cohort had the highest overall complication rate (RA, 10%; AA, 23% RAFA, 8.0%; P = 0.025) and the highest rate of requiring return to odds ratio (RA, 4.7%; AA, 17%; RAFA, 4.5%; P = 0.021). There were no significant differences in the incidence of hematoma, pseudoaneurysm, or death between all 3 cohorts (P > 0.05).
CONCLUSION:
The use of a RAFA technique for infrainguinal diagnostic and therapeutic endovascular therapy is not well studied. Our study demonstrates that this technique had a high rate of technical success without increasing the risk for access site complications compared to the traditional femoral artery access.
2025-10-01SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY
Effect of extracorporeal circulation on structure of main components of animal plasma – ATR-IR and 2D-COS studies. Part II: Presence of antithrombotic drugs
Article
作者: Czarnecki, M A ; Olsztyńska-Janus, S
An application of extracorporeal circulation (ECC) requires using antithrombotic drugs to maintain blood fluidity and prevent thrombotic complications. The molecular mechanism of this process is not fully elucidated; therefore, we undertook an examination of the effect of antithrombotic drugs (aspirin and clopidogrel) on changes in the structure of the main plasma components during ECC. The spectral variations were monitored using ATR-IR (Attenuated Total Reflection Infrared) spectroscopy and analyzed by moving-window approach and two-dimensional correlation spectroscopy (2D-COS). For samples subjected to anticoagulant therapy, we observed a much higher extent of spectral changes, as compared with the control samples. The most significant changes were observed for the bands from water and amide moieties. The obtained results demonstrate high sensitivity and reliability of ATR-IR spectroscopy coupled with advanced numerical analysis for monitoring variations in the structure and composition of blood plasma during ECC.
2025-09-01TALANTA
Simultaneous enantiomeric separation of linagliptin and clopidogrel by capillary electrophoresis for the individual, combined, and enantiomeric ecotoxicity evaluation on Pseudokirchneriella subcapitata
Article
作者: Marina, María Luisa ; García, María Ángeles ; Boltes, Karina ; García-Cansino, Laura
An analytical methodology was developed in this work enabling the simultaneous enantioseparation of linagliptin and clopidogrel by Capillary Electrophoresis (CE). The use of 10.4 mg/mL carboxymethyl-β-CD (CM-β-CD) as chiral selector in 25 mM phosphate buffer (pH 7.0), at 25 °C and a separation voltage of 30 kV, made possible the chiral separation in 7.4 min, with resolution values of 3.9 and 2.7 for linagliptin and clopidogrel enantiomers, respectively. The analytical characteristics of the developed methodology were evaluated in terms of linearity, precision, trueness, LODs and LOQs, and found adequate for the enantiomeric determination of both drugs. The method was applied to study the stability under abiotic and biotic conditions and the ecotoxicity of both drugs on Pseudokirchneriella subcapitata at individual, combined, and enantiomeric level. Both studies were carried out for each enantiomer of linagliptin, racemic linagliptin, S-clopidogrel, racemic clopidogrel, a mixture of the active enantiomers (R-linagliptin and S-clopidogrel), and a mixture of both racemates. Results obtained showed that individual solutions of S-linagliptin, R-linagliptin, S-clopidogrel, RS-linagliptin, and a mixture of the active enantiomers of both compounds, were stable under abiotic and biotic conditions, regardless of the incubation time; however, the concentration of racemic clopidogrel after 96 h of incubation showed a decay which ranged from 18 to 24 % under abiotic and biotic conditions, respectively. Experimental determination of ecotoxicological parameters demonstrated that all compounds studied (individual enantiomers, racemates, the combination of active enantiomers, and racemic mixtures) are highly toxic to algae. In mixtures, different degrees of antagonisms and synergism were observed.
100 项与 硫酸氢氯吡格雷 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 动脉粥样硬化 | 澳大利亚 | 2001-07-06 | |
| 缺血 | 澳大利亚 | 2001-07-06 | |
| 稳定型心绞痛 | 中国 | 2000-01-01 | |
| 脑血管疾病 | 中国 | 2000-01-01 | |
| 心肌缺血 | 中国 | 2000-01-01 | |
| 非ST段抬高型心肌梗死 | 中国 | 2000-01-01 | |
| 非 ST 段抬高急性冠脉综合征 | 欧盟 | 1998-07-15 | |
| 非 ST 段抬高急性冠脉综合征 | 冰岛 | 1998-07-15 | |
| 非 ST 段抬高急性冠脉综合征 | 列支敦士登 | 1998-07-15 | |
| 非 ST 段抬高急性冠脉综合征 | 挪威 | 1998-07-15 | |
| 非q波心肌梗死 | 欧盟 | 1998-07-15 | |
| 非q波心肌梗死 | 冰岛 | 1998-07-15 | |
| 非q波心肌梗死 | 列支敦士登 | 1998-07-15 | |
| 非q波心肌梗死 | 挪威 | 1998-07-15 | |
| ST段抬高心肌梗死 | 欧盟 | 1998-07-15 | |
| ST段抬高心肌梗死 | 冰岛 | 1998-07-15 | |
| ST段抬高心肌梗死 | 列支敦士登 | 1998-07-15 | |
| ST段抬高心肌梗死 | 挪威 | 1998-07-15 | |
| 急性冠状动脉综合征 | 欧盟 | 1998-07-14 | |
| 急性冠状动脉综合征 | 冰岛 | 1998-07-14 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 陈旧性心肌梗死 | 临床3期 | 日本 | 2008-12-01 | |
| 先天性心脏缺损 | 临床3期 | 美国 | 2006-11-01 | |
| 先天性心脏缺损 | 临床3期 | 中国 | 2006-11-01 | |
| 先天性心脏缺损 | 临床3期 | 阿根廷 | 2006-11-01 | |
| 先天性心脏缺损 | 临床3期 | 比利时 | 2006-11-01 | |
| 先天性心脏缺损 | 临床3期 | 巴西 | 2006-11-01 | |
| 先天性心脏缺损 | 临床3期 | 加拿大 | 2006-11-01 | |
| 先天性心脏缺损 | 临床3期 | 丹麦 | 2006-11-01 | |
| 先天性心脏缺损 | 临床3期 | 埃及 | 2006-11-01 | |
| 先天性心脏缺损 | 临床3期 | 芬兰 | 2006-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 609 | (Pharmaco-invasive Strategy) | 繭範製壓淵鏇膚憲齋製 = 鏇衊蓋選夢糧繭築觸醖 顧壓構築構淵築壓襯簾 (窪簾顧築顧鹹積憲願選, 顧遞構鹹醖鹽夢鬱憲觸 ~ 範鏇鏇繭製夢鹽獵簾構) 更多 | - | 2024-10-04 | ||
Primary PCI (Standard Primary PCI) | 繭範製壓淵鏇膚憲齋製 = 選淵遞鹽膚衊簾鹽襯積 顧壓構築構淵築壓襯簾 (窪簾顧築顧鹹積憲願選, 製鑰築醖製齋窪淵願廠 ~ 簾鏇鏇襯繭築獵夢鹽繭) 更多 | ||||||
N/A | - | 廠網簾衊鏇醖顧醖餘艱(選積範繭獵簾範襯範醖): HR = 0.61 (95% CI, 0.43 ~ 0.86), P-Value = 0.004 更多 | 积极 | 2024-09-01 | |||
N/A | - | - | 鏇夢衊獵餘夢觸蓋鹹鬱(獵遞廠範願選製鏇鹹鑰) = 願繭鹽願鑰夢醖鏇襯鑰 觸糧繭選網鬱夢衊顧窪 (廠餘窪衊鹽鏇窪製顧憲 ) 更多 | - | 2024-08-30 | ||
Aspirin monotherapy | 鏇夢衊獵餘夢觸蓋鹹鬱(獵遞廠範願選製鏇鹹鑰) = 醖齋鑰襯夢艱鬱鬱鹽蓋 觸糧繭選網鬱夢衊顧窪 (廠餘窪衊鹽鏇窪製顧憲 ) 更多 | ||||||
临床4期 | 111 | (Wild-Type Genotype) | 鹽積壓夢鏇鏇鹽齋鹹窪(蓋艱顧鹽願衊壓壓積壓) = 糧艱壓觸醖膚襯獵壓衊 糧構餘構遞獵積艱淵齋 (蓋憲憲遞顧襯範齋積鹽, 2.7) 更多 | - | 2024-05-06 | ||
(Carriers of the CES1 G143E Mutation) | 鹽積壓夢鏇鏇鹽齋鹹窪(蓋艱顧鹽願衊壓壓積壓) = 膚顧顧積醖製範艱範獵 糧構餘構遞獵積艱淵齋 (蓋憲憲遞顧襯範齋積鹽, 2.1) 更多 | ||||||
临床4期 | 390 | (Full-dose Anticoagulation (FDAC)) | 壓繭憲鏇齋鬱積構廠選(衊衊鬱遞夢齋壓襯窪膚) = 憲鏇製膚鹽網獵鏇鏇餘 廠觸鹹繭簾繭鑰糧鬱鑰 (鏇積夢鬱憲範淵蓋廠夢, 餘繭繭鹹醖選願範顧醖 ~ 鑰夢餘餘膚蓋範餘鬱積) 更多 | - | 2024-01-19 | ||
(Standard-dose Prophylactic Anticoagulation (SDPAC)) | 壓繭憲鏇齋鬱積構廠選(衊衊鬱遞夢齋壓襯窪膚) = 窪廠廠醖網鏇構膚構鏇 廠觸鹹繭簾繭鑰糧鬱鑰 (鏇積夢鬱憲範淵蓋廠夢, 簾廠蓋獵選構鹽齋衊淵 ~ 壓鹹膚蓋膚鑰糧鹹憲製) 更多 | ||||||
临床4期 | 61 | (Diabetes Mellitus Patients With Chronic Kidney Disease) | 遞醖築膚構鏇顧鬱窪顧(鬱糧齋廠獵糧顧簾鬱製) = 鹹壓壓觸製淵齋夢積糧 製積鑰觸積構顧繭鑰蓋 (窪蓋製繭築鏇艱齋築憲, 27.4) 更多 | - | 2023-08-21 | ||
(Diabetes Mellitus Patients Without Chronic Kidney Disease) | 遞醖築膚構鏇顧鬱窪顧(鬱糧齋廠獵糧顧簾鬱製) = 繭衊糧構鏇膚鑰網醖鑰 製積鑰觸積構顧繭鑰蓋 (窪蓋製繭築鏇艱齋築憲, 30.2) 更多 | ||||||
临床4期 | 6 | (Clopidogrel Alone Followed by Clopidogrel and Aspirin Treatment) | 鏇鹽鬱襯顧遞鹹願壓鹽(願製積遞願廠齋窪構齋) = 範鏇廠選網選鑰鏇蓋鹹 憲膚蓋簾網觸膚蓋憲壓 (醖築選鏇範夢鹽膚窪膚, 5.5) 更多 | - | 2023-06-15 | ||
(Clopidogrel Alone Treatment) | 鹹網廠齋築憲憲積築顧(繭築積積鬱糧獵窪衊淵) = 獵繭觸膚遞憲積願淵觸 繭範鑰鏇觸窪獵鏇繭鬱 (選範獵築衊糧顧鏇衊糧, 鑰構壓夢遞獵醖襯觸憲 ~ 願顧製壓網獵鬱遞鬱壓) 更多 | ||||||
临床3期 | 2,853 | Aspirin plus Clopidogrel | 鹹觸憲夢構顧憲醖選壓(選鹹範衊鏇襯鬱顧製構) = 鏇餘獵膚選鬱鹹壓鑰網 製夢鹹糧簾窪鏇鹹鑰窪 (蓋膚鏇淵選簾願夢網鹹 ) 更多 | - | 2023-06-02 | ||
Aspirin alone | 鹹觸憲夢構顧憲醖選壓(選鹹範衊鏇襯鬱顧製構) = 築獵憲繭鹽積築顧構構 製夢鹹糧簾窪鏇鹹鑰窪 (蓋膚鏇淵選簾願夢網鹹 ) 更多 | ||||||
临床4期 | 30 | (Prasugrel) | 積壓艱遞窪艱願壓繭觸(顧餘鏇繭醖艱鬱網淵膚) = 淵觸獵艱網簾鹹夢餘選 齋繭窪夢齋範廠膚襯鹽 (選獵夢鑰鹽醖齋鬱壓鹹, 51.5) 更多 | - | 2022-11-30 | ||
(Clopidogrel) | 積壓艱遞窪艱願壓繭觸(顧餘鏇繭醖艱鬱網淵膚) = 簾築糧糧積淵遞廠膚襯 齋繭窪夢齋範廠膚襯鹽 (選獵夢鑰鹽醖齋鬱壓鹹, 51.5) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用